
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI Inc is demonstrating a strong potential for growth, as reflected in the raised price target based on a higher EV/sales multiple of 10.9x, highlighting anticipated 2026 sales of $1,568 million. This upward revision is indicative of the favorable valuation attributed to the foundation model's impact on the data and clinical businesses, emphasizing the company's commitment to enhance diagnostic accuracy through AI technology. Furthermore, the strategic partnership with AZN.LON and Pathos AI for a multimodal database aims to bolster oncology research, underscoring Tempus AI's position as a key player in transforming healthcare data utilization.
Bears say
Tempus AI Inc faces significant competitive pressures in the genomics testing market, which could adversely impact its market position and revenue generation. Additionally, the company is exposed to reimbursement risks associated with existing tests due to potential changes in policies from the Centers for Medicare & Medicaid Services (CMS) and other payors, as well as uncertainties surrounding the reimbursement landscape for newly introduced products like Algos. Furthermore, potential regulatory changes affecting patient and data privacy could hinder Tempus' ability to effectively acquire and utilize critical healthcare data, posing further threats to its operational capabilities.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares